dehydroxymethylepoxyquinomicin and Atherosclerosis

Atherosclerosis is a chronic inflammatory process, and anti-inflammatory agents potentially inhibit the development of atherosclerosis. We tested whether a novel NFkappaB inhibitor reduces atherosclerosis.. Dehydroxymethylepoxyquinomicin (10 mg/kg) or vehicle (chloromethyl cellulose) was injected intraperitoneally into apoE-deficient mice three times a week for 16 weeks. The entire aorta was excised and atherosclerotic area was determined at 4 and 16 weeks. Serum levels of cholesterol, triglyceride, TNF-alpha and adiponectin were also measured.. The atherosclerotic area was significantly smaller in mice treated with dehydroxymethyl-epoxyquinomicin both at 4 and 16 weeks. There was no significant difference in body weight or serum levels of cholesterol, triglyceride, and adiponectin.. A new NFkappaB inhibitor, dehydroxymethylepoxyquinomicin, reduced atherosclerosis without affecting plasma lipid levels in apoE-deficient mice.

Topics: Adiponectin; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Benzamides; Body Weight; Cholesterol; Cyclohexanones; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Triglycerides; Tumor Necrosis Factor-alpha